BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang A, Fox SH. Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management. Drugs. 2016;76:1093-1118. [PMID: 27312429 DOI: 10.1007/s40265-016-0600-5] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Guilhemsang L, Gutierrez-Ceballos A, Antonazzo M, Mallet NP, Ugedo L, Morera-Herreras T. Preferential Modulatory Action of 5-HT(2A) Receptors on the Dynamic Regulation of Basal Ganglia Circuits. J Neurosci 2023;43:56-67. [PMID: 36400530 DOI: 10.1523/JNEUROSCI.1181-22.2022] [Reference Citation Analysis]
2 Lipari N, Centner A, Glinski J, Cohen S, Manfredsson FP, Bishop C. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease. Neurobiol Dis 2023;176:105965. [PMID: 36526089 DOI: 10.1016/j.nbd.2022.105965] [Reference Citation Analysis]
3 Li G, Zhu J, Wu X, Liu T, Hu P, Tian Y, Wang K. Baseline free water within the visual processing system predicts future psychosis in Parkinson disease. Eur J Neurol 2022. [PMID: 36583634 DOI: 10.1111/ene.15668] [Reference Citation Analysis]
4 Fischer CE, Namasivayam A, Crawford-Holland L, Hakobyan N, Schweizer TA, Munoz DG, Pollock BG. Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment. Psychiatr Clin North Am 2022;45:691-705. [PMID: 36396273 DOI: 10.1016/j.psc.2022.07.001] [Reference Citation Analysis]
5 Szarpak J, Drożak P, Piwoński M, Wróblewski H, Morylowska-topolska J. Should patients with Parkinson’s disease only visit a neurologist’s office? - a narrative review of neuropsychiatric disorders among people with Parkinson’s disease. Current Problems of Psychiatry 2022;0. [DOI: 10.2478/cpp-2022-0021] [Reference Citation Analysis]
6 Angelopoulou E, Bougea A, Papageorgiou SG, Villa C. Psychosis in Parkinson's Disease: A Lesson from Genetics. Genes (Basel) 2022;13:1099. [PMID: 35741861 DOI: 10.3390/genes13061099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kwan C, Huot P. An overview of the active clinical trials for Parkinson's disease psychosis. Neurodegener Dis Manag 2022. [PMID: 35592949 DOI: 10.2217/nmt-2022-0020] [Reference Citation Analysis]
8 Patel V, Ts J, Kamble N, Yadav R, K T, Pal PK, Reddy Yc J. Prevalence and Correlates of Psychiatric Comorbidity and Multimorbidity in Parkinson's Disease and Atypical Parkinsonian Syndromes. J Geriatr Psychiatry Neurol 2022;:8919887221103575. [PMID: 35579346 DOI: 10.1177/08919887221103575] [Reference Citation Analysis]
9 Kwan C, Frouni I, Huot P. Pharmacotherapy of Psychosis in Parkinson’s Disease. NeuroPsychopharmacotherapy 2022. [DOI: 10.1007/978-3-030-62059-2_439] [Reference Citation Analysis]
10 Montagnese M, Vignando M, Ffytche D, Mehta MA. Cognitive and visual processing performance in Parkinson's disease patients with vs without visual hallucinations: A meta-analysis. Cortex 2021;146:161-72. [PMID: 34864505 DOI: 10.1016/j.cortex.2021.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lauretani F, Ruffini L, Testa C, Salvi M, Scarlattei M, Baldari G, Zucchini I, Lorenzi B, Cattabiani C, Maggio M. Cognitive and Behavior Deficits in Parkinson's Disease with Alteration of FDG-PET Irrespective of Age. Geriatrics (Basel) 2021;6:110. [PMID: 34842741 DOI: 10.3390/geriatrics6040110] [Reference Citation Analysis]
12 Frouni I, Belliveau S, Maddaford S, Nuara SG, Gourdon JC, Huot P. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. Eur J Pharmacol 2021;910:174452. [PMID: 34480885 DOI: 10.1016/j.ejphar.2021.174452] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Fujii C. The post-diagnosis sleep quality of patients with Parkinson's disease. British Journal of Neuroscience Nursing 2021;17:148-154. [DOI: 10.12968/bjnn.2021.17.4.148] [Reference Citation Analysis]
14 Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, Johnson R, Chernick D, Hubble J. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis 2020;10:543-58. [PMID: 31929122 DOI: 10.3233/JPD-191841] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
15 Aubignat M. Clozapine-related immunodeficiency: Implications for Parkinson's disease psychosis in the context of the COVID-19 pandemic. Rev Neurol (Paris) 2021:S0035-3787(21)00584-1. [PMID: 34217512 DOI: 10.1016/j.neurol.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Radojević B, Dragašević-Mišković NT, Marjanović A, Branković M, Dobričić V, Milovanović A, Tomić A, Svetel M, Petrović I, Jančić I, Stanisavljević D, Savić MM, Kostić VS. Clinical and Genetic Analysis of Psychosis in Parkinson's Disease. J Parkinsons Dis 2021. [PMID: 34151861 DOI: 10.3233/JPD-212716] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Küpeli Akkol E, Tatlı Çankaya I, Şeker Karatoprak G, Carpar E, Sobarzo-Sánchez E, Capasso R. Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases. Front Pharmacol 2021;12:669638. [PMID: 34054540 DOI: 10.3389/fphar.2021.669638] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
18 De Deurwaerdère P, Chagraoui A, Di Giovanni G. Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence. Prog Brain Res 2021;261:161-264. [PMID: 33785130 DOI: 10.1016/bs.pbr.2021.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wei X, Cai M, Jin L. The Function of the Metals in Regulating Epigenetics During Parkinson's Disease. Front Genet 2020;11:616083. [PMID: 33603768 DOI: 10.3389/fgene.2020.616083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Diaz NA. Schizophrenia and Other Psychotic Disorders. Absolute Geriatric Psychiatry Review 2021. [DOI: 10.1007/978-3-030-58663-8_13] [Reference Citation Analysis]
21 Kwan C, Frouni I, Huot P. Pharmacotherapy of Psychosis in Parkinson’s Disease. NeuroPsychopharmacotherapy 2021. [DOI: 10.1007/978-3-319-56015-1_439-1] [Reference Citation Analysis]
22 Bhoopatiraju S, Grossberg G, Saint Louis University School of Medicine, St Louis, MO, USA, Saint Louis University School of Medicine, St Louis, MO, USA. Emerging Perspectives in the Diagnosis and Management of Depression and Psychosis in Parkinson's Disease. Neurology 2021;17:97. [DOI: 10.17925/usn.2021.17.2.97] [Reference Citation Analysis]
23 Ghoreishi SA, As'adi H. Functional Neurological Symptom Disorder in a Patient with Parkinson’s Disease and Psychotic Features: A Case Report. J Kermanshah Univ Med Sci 2020;24. [DOI: 10.5812/jkums.94186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 El Otmani H, Sabiry S, Bellakhdar S, El Moutawakil B, Abdoh Rafai M. Othello syndrome in Parkinson's disease: A diagnostic emergency of an underestimated condition. Rev Neurol (Paris) 2021;177:690-3. [PMID: 33276961 DOI: 10.1016/j.neurol.2020.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Díaz-Santos M, Monge ZA, Salazar RD, Gilmore GC, Neargarder S, Cronin-Golomb A. Increasing Contrast Improves Object Perception in Parkinson's Disease with Visual Hallucinations. Mov Disord Clin Pract 2021;8:51-9. [PMID: 33426159 DOI: 10.1002/mdc3.13104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Kwan C, Nuara SG, Bédard D, Gaudette F, Gourdon JC, Beaudry F, Huot P. Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset. Neuropharmacology 2021;182:108386. [PMID: 33152452 DOI: 10.1016/j.neuropharm.2020.108386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Nakahara K, Kurisaki R, Nakane S, Sakamoto T, Ikeda T, Yamashita T, Uekawa K, Ando Y. Correlation between urinary incontinence and psychosis in patients with advanced‐stage Parkinson’s disease. Neurology & Clinical Neurosc 2020;8:385-389. [DOI: 10.1111/ncn3.12435] [Reference Citation Analysis]
28 Mouchaileh N, Hughes AJ. Pharmacological management of Parkinson’s disease in older people. J Pharm Pract Res 2020;50:445-454. [DOI: 10.1002/jppr.1683] [Reference Citation Analysis]
29 Greger J, Aladeen T, Rainka M, Kale A, Capote H. Evaluating rates of reporting symptoms of Parkinson's disease psychosis: provider versus targeted questionnaire. Int J Neurosci 2022;132:459-65. [PMID: 32910866 DOI: 10.1080/00207454.2020.1821678] [Reference Citation Analysis]
30 Kwan C, Huot P. 5-HT3 receptors in Parkinson's disease psychosis: a forgotten target? Neurodegener Dis Manag 2019;9:251-3. [PMID: 31580227 DOI: 10.2217/nmt-2019-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
31 Drake R. Clozapine. Seminars in Clinical Psychopharmacology 2020. [DOI: 10.1017/9781911623465.012] [Reference Citation Analysis]
32 Knolle F, Garofalo S, Viviani R, Justicia A, Ermakova AO, Blank H, Williams GB, Arrondo G, Ramachandra P, Tudor-Sfetea C, Bunzeck N, Duezel E, Robbins TW, Barker RA, Murray GK. Altered subcortical emotional salience processing differentiates Parkinson's patients with and without psychotic symptoms.Neuroimage Clin. 2020;27:102277. [PMID: 32540629 DOI: 10.1016/j.nicl.2020.102277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
33 Butala A, Shepard M, Pontone G. Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics. Handb Clin Neurol 2019;165:83-121. [PMID: 31727232 DOI: 10.1016/B978-0-444-64012-3.00007-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
34 Wang T, Li C, Han B, Wang Z, Meng X, Zhang L, He J, Fu F. Neuroprotective effects of Danshensu on rotenone-induced Parkinson's disease models in vitro and in vivo. BMC Complement Med Ther 2020;20:20. [PMID: 32020857 DOI: 10.1186/s12906-019-2738-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
35 Kohl Z, Winkler J. Serotonin in Parkinson's disease. Handbook of Behavioral Neuroscience 2020. [DOI: 10.1016/b978-0-444-64125-0.00050-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Cherif Mghari D. Mécanisme d’action de la pimavansérine : le nouvel antipsychotique pour traiter la psychose parkinsonienne. Annales Médico-psychologiques, revue psychiatrique 2019;177:1010-2. [DOI: 10.1016/j.amp.2019.09.008] [Reference Citation Analysis]
37 Cotterell P, Weight D, Joseph S, Joseph P. Complex Parkinson's disease: review and experiences. British Journal of Healthcare Assistants 2019;13:394-400. [DOI: 10.12968/bjha.2019.13.8.394] [Reference Citation Analysis]
38 Lenka A, Pagonabarraga J, Pal PK, Bejr-Kasem H, Kulisvesky J. Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications. Neurology 2019;93:259-66. [PMID: 31289146 DOI: 10.1212/WNL.0000000000007913] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
39 Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm (Vienna) 2019;126:933-95. [PMID: 31214855 DOI: 10.1007/s00702-019-02028-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
40 Tampi RR, Tampi DJ, Young JJ, Balachandran S, Hoq RA, Manikkara G. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. World J Psychiatr 2019; 9(3): 47-54 [PMID: 31211112 DOI: 10.5498/wjp.v9.i3.47] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
41 Cotterell P, Weight D, Joseph S, Joseph P. Complex Parkinson's disease: review and experiences. British Journal of Neuroscience Nursing 2019;15:140-145. [DOI: 10.12968/bjnn.2019.15.3.140] [Reference Citation Analysis]
42 Buhmann C, Mainka T, Ebersbach G, Gandor F. Evidence for the use of cannabinoids in Parkinson's disease. J Neural Transm (Vienna) 2019;126:913-24. [PMID: 31131434 DOI: 10.1007/s00702-019-02018-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
43 Falso M, Grillo M, Righetti A, Lopa F, Rocco L, Facchi E. Postural and Kynematic effect of a new custom-made foot insole called “Prodynamic” in a cohort of patients affected by extrapiramidal disease. J Nov Physiother Rehabil 2019;3:039-081. [DOI: 10.29328/journal.jnpr.1001027] [Reference Citation Analysis]
44 Seritan AL, Ureste P, Duong T, Ostrem JL. Psychopharmacology for Patients with Parkinson’s Disease and Deep Brain Stimulation: Lessons Learned in an Academic Center. CPSP 2019;8:41-54. [DOI: 10.2174/2211556007666180328142953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Prasad S, Pal PK. When time is of the essence: Managing care in emergency situations in Parkinson's disease. Parkinsonism & Related Disorders 2019;59:49-56. [DOI: 10.1016/j.parkreldis.2018.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Hess CW, Okun MS, Ramirez-zamora A. Challenges in Defining Inappropriate Medication Use in Parkinson Disease Dementia. JAMA Neurol 2019;76:17. [DOI: 10.1001/jamaneurol.2018.2826] [Reference Citation Analysis]
47 Miyasaki JM. Parkinson’s Disease and Related Disorders. Neuropalliative Care 2019. [DOI: 10.1007/978-3-319-93215-6_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Huot P. 5-HT2A receptors and Parkinson's disease psychosis: a pharmacological discussion. Neurodegener Dis Manag 2018;8:363-5. [PMID: 30451579 DOI: 10.2217/nmt-2018-0039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
49 Katz M, Goto Y, Kluger BM, Galifianakis NB, Miyasaki JM, Kutner JS, Jones CA, Pantilat SZ. Top Ten Tips Palliative Care Clinicians Should Know About Parkinson's Disease and Related Disorders. J Palliat Med 2018;21:1507-17. [PMID: 30204543 DOI: 10.1089/jpm.2018.0390] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
50 Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry 2018;17:341-56. [PMID: 30192094 DOI: 10.1002/wps.20567] [Cited by in Crossref: 168] [Cited by in F6Publishing: 180] [Article Influence: 33.6] [Reference Citation Analysis]
51 Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-22. [PMID: 28777755 DOI: 10.3233/JPD-171134] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
52 Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin 2017;7:262-70. [PMID: 29955532 DOI: 10.9740/mhc.2017.11.262] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
53 Lanza K, Bishop C. Serotonergic targets for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna) 2018;125:1203-16. [PMID: 29305656 DOI: 10.1007/s00702-017-1837-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
54 Schneider RB, Iourinets J, Richard IH. Parkinson's disease psychosis: presentation, diagnosis and management. Neurodegenerative Disease Management 2017;7:365-76. [DOI: 10.2217/nmt-2017-0028] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 13.3] [Reference Citation Analysis]
55 Morgan JC, Kurek JA, Davis JL, Sethi KD. Insights into Pathophysiology from Medication-induced Tremor. Tremor Other Hyperkinet Mov (N Y) 2017;7:442. [PMID: 29204312 DOI: 10.7916/D8FJ2V9Q] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
56 Chen C, Zheng H, Hu Z. Association between Parkinson's disease and risk of prostate cancer in different populations: An updated meta-analysis. Sci Rep 2017;7:13449. [PMID: 29044216 DOI: 10.1038/s41598-017-13834-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
57 Kianirad Y, Simuni T. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Expert Rev Clin Pharmacol 2017;10:1161-8. [PMID: 28817967 DOI: 10.1080/17512433.2017.1369405] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
58 Warren N, O'Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry 2017;88:1060-4. [PMID: 29018160 DOI: 10.1136/jnnp-2017-315985] [Cited by in Crossref: 61] [Cited by in F6Publishing: 101] [Article Influence: 10.2] [Reference Citation Analysis]
59 Woolston AL, Hsiao PC, Kuo PH, Wang SH, Lien YJ, Liu CM, Hwu HG, Lu TP, Chuang EY, Chang LC, Chen CH, Wu JY, Tsuang MT, Chen WJ. Genetic loci associated with an earlier age at onset in multiplex schizophrenia. Sci Rep 2017;7:6486. [PMID: 28744025 DOI: 10.1038/s41598-017-06795-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
60 Huot P, Sgambato-Faure V, Fox SH, McCreary AC. Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update. ACS Chem Neurosci 2017;8:973-86. [PMID: 28460160 DOI: 10.1021/acschemneuro.6b00440] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
61 Onofrj M, Carrozzino D, D'Amico A, Di Giacomo R, Delli Pizzi S, Thomas A, Onofrj V, Taylor JP, Bonanni L. Psychosis in parkinsonism: an unorthodox approach. Neuropsychiatr Dis Treat 2017;13:1313-30. [PMID: 28553118 DOI: 10.2147/NDT.S116116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
62 Carrozzino D, Bech P, Patierno C, Onofrj M, Morberg BM, Thomas A, Bonanni L, Fulcheri M. Somatization in Parkinson's Disease: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry 2017;78:18-26. [PMID: 28522290 DOI: 10.1016/j.pnpbp.2017.05.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
63 Frei K, Truong DD. Hallucinations and the spectrum of psychosis in Parkinson's disease. Journal of the Neurological Sciences 2017;374:56-62. [DOI: 10.1016/j.jns.2017.01.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
64 Balestrino R, Martinez-martin P. Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease. Journal of the Neurological Sciences 2017;373:173-8. [DOI: 10.1016/j.jns.2016.12.060] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
65 Balestrino R, Martinez-Martin P. Reprint of "Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease". J Neurol Sci 2017;374:3-8. [PMID: 28109579 DOI: 10.1016/j.jns.2017.01.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
66 Adis Medical Writers. Manage psychosis in Parkinson’s disease using a stepwise approach. Drugs Ther Perspect 2017;33:16-21. [DOI: 10.1007/s40267-016-0362-x] [Reference Citation Analysis]
67 Ehgoetz Martens KA, Lewis SJ. Pathology of behavior in PD: What is known and what is not? J Neurol Sci 2017;374:9-16. [PMID: 28089250 DOI: 10.1016/j.jns.2016.12.062] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
68 Rosa-grilo M, Qamar MA, Evans A, Chaudhuri KR. The efficacy of apomorphine – A non-motor perspective. Parkinsonism & Related Disorders 2016;33:S28-35. [DOI: 10.1016/j.parkreldis.2016.11.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
69 Di Giovanni G, Svob Strac D, Sole M, Unzeta M, Tipton KF, Mück-Šeler D, Bolea I, Della Corte L, Nikolac Perkovic M, Pivac N, Smolders IJ, Stasiak A, Fogel WA, De Deurwaerdère P. Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. Front Neurosci 2016;10:541. [PMID: 27932945 DOI: 10.3389/fnins.2016.00541] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
70 Stahl SM. Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr 2016;21:355-9. [DOI: 10.1017/s1092852916000602] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]